Jonathan Seth Wilensky MD MBA, FACS

Diplomate, The American Board of Plastic Surgery

https://www.linkedin.com/in/jonwilenskymdmba/

#### PERSONAL

Jon S. Wilensky MD Inc. PO Box 12052 La Jolla, CA 92039 Phone:(858) 622-0200 FAX: (858) 947-2016 E-mail: drwilensky@wilenskymd.com Direct Cell: (858) 945-5720

#### EMPLOYMENT

#### Consulting Surgeon, Beautologie Cosmetic Surgery and Medical Aesthetics

Beautologie Bakersfield Surgery Center, Bakersfield, CA Beautologie Fresno Surgery Center, Fresno, CA June 10, 2021 to present (Patient Volume: 200+/yr)

https://www.beautologie.com

## Head of Surgery, ViaCyte, Inc. (Acquired by Vertex Pharmaceuticals July 11, 2022)

ViaCyte was a regenerative medicine company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for all type 1 diabetes and a next-generation treatment for insulin-requiring type 2 diabetes. Acquired for \$320M by Vertex, a publicly traded global pharmaceutical company.

https://www.businesswire.com/news/home/20220711005280/en/Vertex-to-Acquire-ViaCyte-With-the-Goal-of-Accelerating-its-Potentially-Curative-VX-880-Programs-in-Type-1-Diabetes

https://www.prnewswire.com/news-releases/viacyte-appoints-dr-jon-wilensky-ashead-of-surgery-301338128.html June 21, 2021 to March 17, 2023 (Head of Surgery) June 2014 to June 2021 (Surgical & Technical Consultant)

#### North County Trauma Associates, Inc.

A provider of Level II Trauma Surgery services to San Diego County. Boardcertified Plastic Surgeon and Shareholder. On-call coverage provided to Scripps Health and Palomar Health (Mayo Clinic Care Network) Level II Hospitals. Services provided included: Oral & Maxillofacial Surgery (OMFS) Trauma, Hand & Upper Extremity Trauma, and General Plastic & Reconstructive Surgery. 6 days per month x 15 years. Total service – over 1000 days of call coverage. July 2006 to June 2021

#### Cofounder & VP, Clinical Development, Visicell Medical Inc.

A provider of safe and biodegradable stem cell tracking tools intended to accelerate stem cell-based therapy to the market for patients who are afflicted with devastating and currently incurable diseases. August 2020 to November 2021

#### Consulting Surgeon, The Grossman Burn Center

Bakersfield Memorial Hospital, Dignity Health, Bakersfield, CA West Hills Hospital & Medical Center, HCA Far West, Los Angeles, CA Research Medical Center, HCA Midwest Health, Kansas City, MO October 1, 2017 to October 31, 2019

#### **Cofounder, Braykion Inc.**

A digital health technology startup with a proprietary, patent-pending wearable sensor solution to ensure compliance with healthcare hand washing guidelines January 8, 2016 to June 22, 2020

## University of California – San Diego (UCSD), Associate Physician

Department of Medicine, Division of Endocrinology/Metabolism August 1, 2015 to July 31, 2016

# University of California – San Diego (UCSD), Clinical Assistant Professor (Vol)

Department of Surgery, Division of Plastic Surgery November 1, 2014 to September 30, 2017

#### Private Practice, La Jolla, California

July 1, 2006 to present

University of Michigan Health System, Ann Arbor, MI		
Chief Resident in Plastic Surgery	July 2005 to June 2006	
Senior Resident in Plastic Surgery	July 2004 to June 2005	
Senior Resident in General Surgery	July 2001 to June 2004	
General Surgical Internship	June 2000 to June 2001	

## HOSPITAL APPOINTMENTS

Scripps Green Hospital, Scripps Health, La Jolla, CA Palomar Medical Center, Mayo Clinic Care Network, Escondido, CA

## CERTIFICATIONS

CITI Good Clinical Practice (GCP) Course, Credential #15365077, through April 2026 Diplomate, The American Board of Plastic Surgery, November 2007, Certificate #7373 Maintenance of Certification, The American Board of Plastic Surgery, June 2017

## EDUCATION

**University of California – San Diego, Rady School of Management**, La Jolla, CA; September 2015-June 2017 (MBA)

**University of Michigan Medical School**, Ann Arbor, MI; August 1996-June 2000 (MD)

University of Michigan, Ann Arbor, MI; August 1993-May 1997 (BS)

**Stuyvesant High School**, New York, NY; September 1989-June 1993 (HS)

#### HONORS

United States Patent. **Patent No.: 10,660,550**. Implantable Sensor Apparatus and Methods. Date of Patent: May 26, 2020.

Braykion, 2<sup>nd</sup> Place, **UC San Diego Triton Innovation Challenge**, November 2016

Braykion, Featured Innovation Alley Company, TEDx San Diego, October 2016

Braykion, 2<sup>nd</sup> Place, **10<sup>th</sup> Annual John G. Watson San Diego Tech Coast Angels Quick Pitch Competition**, October 2016

Braykion, 2<sup>nd</sup> Place, Tech-Innovation Track, **UC San Diego Entrepreneur Challenge \$100,000 Business Plan Competition**, May 2016

Braykion, 2<sup>nd</sup> Place, **UC San Diego Elevator Pitch Competition**, April 2016

Recipient, **Israel Immersion Program Educational Grant**, US-Israel Center on Innovation & Economic Stability, Rady School of Management, Fall 2015

Recipient, **Emerging Leaders Fellowship**, Rady School of Management FlexWeekend MBA Program; Individuals selected will demonstrate a commitment to the region and to their industry, significant contributions to their organizations and the potential to make a significant impact in sustaining and enhancing San Diego's innovation-focused business community.

Physician of the Year, Operating Room, Palomar Medical Center, 2009

**Alpha Omega Alpha**, Honor Medical Society, elected as a House Officer in Plastic Surgery, Alpha Chapter of the University of Michigan Medical School, March 2005

Department of Veterans Affairs, VA Ann Arbor Healthcare System, **House Officer** of the Month, February 2004

Doctor of Medicine conferred with **Distinction in Research** from the University of Michigan Medical School, June 2000

Recipient of the **C. Gardner Child, III, Award for Excellence in Surgery as a Medical Student**, June 2000

Recipient of the **Association for Academic Surgery Student Research Award**, June 2000

Invited **Co-chair** of the **Junior Investigator Session** at the 56<sup>th</sup> Annual Meeting of the American Cleft Palate-Craniofacial Association (ACPA), Scottsdale, AZ, April 1999

Recipient of the **Junior Investigator Award** at the 55<sup>th</sup> Annual Meeting of the American Cleft Palate-Craniofacial Association (ACPA) for research entitled, "Development of a Unique Rodent Model of Mandibular Distraction Osteogenesis," Baltimore, MD, April 1998

Bachelor of Science in Biomedical Sciences conferred with **High Distinction** (3.843) from the University of Michigan as a student in the 7-year integrated premedical-medical program (Inteflex), May 1997

Phi Beta Kappa, March 1996

## CURRENT RETAINED CONSULTANT AGREEMENTS

Novo Nordisk, Inc. / Aspect Biosystems, Inc. Novo Nordisk and Aspect Biosystems are working together to develop bioprinted tissue therapeutics (BTTs) designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration leverages Aspect's proprietary bioprinting technology and Novo Nordisk's expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Aspect has developed a platform technology that will allow for development of a novel class of cell-based medicine designed to be biologically functional, encapsulated to be immune-protective, and suitable for surgical implantation. Novo Nordisk has developed expertise to differentiate stem cells into a wide array of cells that may be used to replace damaged and lost cells which could lead to a specific disease. such as insulin-producing beta cells in type 1 diabetes, as well as manufacturing capabilities to produce the cells at scale. The collaboration focuses on developing BTTs designed to maintain normal blood glucose levels without the need for immunosuppression, which may represent a transformative treatment for people living with type 1 diabetes.

## Bioprinted Tissue Therapeutics Explainer: https://youtu.be/BDdMxjq\_M4g

**Encellin, Inc.** Encellin's cell encapsulation device (CED) is based on over 10 years of research from the Desai lab at UCSF focused on the refinement of nanofabricated membranes with well-defined pore structures. Their CED is constructed of proprietary nanoporous materials resulting in a compliant polymeric implant that can be implanted in a minimally invasive way. When implanted, the CED supports encapsulated cell function and viability without eliciting a foreign body response. Encellin's technology aims to remove the need

for conventional immunosuppression, thereby enabling transplantation of a number of therapeutic cell types. Encellin's CED in combination with a cell-based therapy can provide a safe and smart therapeutic approach for a variety of indications.

**CARI Health, Inc.** CARI Health is developing a wearable medication monitor that measures drug metabolization rates in the interstitial fluid for 2 purposes; 1. to personalize dosing and 2. to monitor adherence. In real time. Conceptually it is very similar to glucose monitoring, but instead of glucose CARI Health measures medications. While the monitor can measure many medications, CARI Health is proving its platform capability first with methadone, a medication used to treat opioid addiction. They intend to make a positive impact on the opioid crisis, which is costing the United States more than \$1 Trillion annually. MedStat Supplies, which serves 70% of the clinics that comprise the target market, has signed letter of intent (LOI) to distribute the product when it enters the market. CARI previously raised \$4.3M in non-dilutive grant funding, followed by a \$2.3M seed round from smart angel investors, including NuFund, Cove Fund, San Diego Angels, Chemical Angels and Medical Devices of Tomorrow.

**BrainXell Therapeutics, Inc.** BrainXell focuses on neural cells for therapeutic development. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells and provides large-scale production of highly enriched, functionally specialized neural cells to the pharmaceutical and biotechnology industry. BrainXell also aims to develop stem cell therapy for neurological injuries and diseases through collaboration with pharmaceutical and healthcare industry. BrainXell's mission is to make our brain healthy and well.

**Visicell Medical, Inc.** Cell-based therapy offers promising treatment solutions for many devastating and currently incurable diseases such as Parkinson's, Alzheimer's, stroke, and cancer. However, the lack of means to effectively track these therapeutic cells in a subject to assess treatment safety and effectiveness lengthens the time for development and introduction of these therapies to clinics. Visicell's singular goal is to help accelerate cell-based therapy to the market for patients in need. We all have been personally touched by the need of such promising therapy for our family, friends and colleagues. With Visicell's technology, the objective is to make such breakthroughs possible for patients. The current suite of imaging tools empowers scientists and clinicians to evaluate cell therapy in a faster, more cost-effective way early on in development, and understand safety and performance with continuity from pre-clinical stage to clinical trials. Visicell strives to transform how biopharmaceutical products are developed and taken to market with their proprietary nanomaterial technology.

## PRIOR RETAINED CONSULTANT AGREEMENTS

**GlySens Incorporated**, was a privately held corporation devoted to developing the world's first *truly* long-term continuous glucose monitoring system, intended to dramatically improve the lives of people with diabetes. The GlySens fully implanted sensor—demonstrated up to 18-month lifetime in preclinical testing wirelessly linked to a convenient external receiver, designed to provide continuous, at-a-glance glucose measurement, recording, and alerts regarding hypo- and hyperglycemic glucose excursions. The GlySens ICGM system underwent clinical evaluation; Phase I, IIa & IIb human implant trials were completed.

**ViaCyte, Inc.**, was a leader in the emerging field of regenerative medicine, and was headquartered in San Diego, California. ViaCyte's innovative product was based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01<sup>™</sup>), with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device (Encaptra® drug delivery system). Once implanted, the precursor cells matured into endocrine cells that secreted insulin and other hormones in a regulated manner to control blood glucose levels. ViaCyte's goal was a product that could free patients with type 1 and type 2 diabetes from long-term insulin dependence. ViaCyte received substantial financial support from both the California Institute for Regenerative Medicine (CIRM) and JDRF. The company was acquired by Vertex Pharmaceuticals in July 2022.

## **PUBLICATIONS & PRESENTATIONS**

A.M. James Shapiro, David Thompson, Thomas W. Donner, Melena D. Bellin, Willa Hsueh, Jeremy Pettus, **Jon Wilensky**, Mark Daniels, Richard M. Wang, Eugene P. Brandon, Manasi S. Jaiman, Evert J. Kroon, Kevin A. D'Amour, and Howard L. Foyt. Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Medicine *2*, 100466, December 21, 2021.

https://doi.org/10.1016/j.xcrm.2021.100466

**J Wilensky MD MBA FACS**; T Cook PA; R Williams MHS MD DABS; ML Garcia MD; B Hafner PA; K Richards PA; B Evans MD; AM Majidian MD; M Young MD; PH Grossman MD FACS. Modernizing the Mechanics of Surgical Excision and Grafting. Video Session: "Burn Care: How I Do It." 52<sup>nd</sup> Annual Meeting of the American Burn Association, March 17-20, 2020, Orlando, FL.

R Williams, MHS MD DABS; T Cook PA; **J Wilensky MD MBA FACS**; P Grossman MD FACS. Management of a Rare Morel-Lavallée Lesion with Skin Necrosis and Concomitant Full-Thickness Burn Using the VERAFLO<sup>™</sup> VAC. 42<sup>nd</sup> Annual Boswick Burn & Wound Symposium, January 25-30, 2020, Maui, HI.

RR Henry, J Pettus, **J Wilensky**, J Shapiro, P Senior, B Roep, R Wang, E Kroon, M Scott, K D'Amour, and HL Foyt. Initial Clinical Evaluation of VC-01<sup>™</sup> Combination Product—A Stem Cell-Derived Islet Replacement for Type 1 Diabetes (T1D), American Diabetes Association (ADA) 78th Scientific Sessions, June 22-26, 2018, Orlando, FL.

Lucisano, J, Kurbanyan, L, Martha S, Routh, T, **Wilensky JS**. "Clinical Update with a Long Term, Unobtrusive Fully-Implanted Continuous Glucose Monitoring System." *Diabetes Technology & Therapeutics*. February 2017, 19(S1): A-1-A-133.

**Wilensky, JS**, Chen, PH. "JET Lasik, Accelerating Ocular Healing by Cell Transplantation." Presented at the 2016 Texas Life Sciences Venture Forum, Houston, TX, May 2016.

**Wilensky, JS**. "Disruptive Technology to Transform Healthcare." Invited Lecturer at the UC San Diego Rady School of Management, Prof. Kevin Zhu, Technology & Innovation Strategy, March 2016.

**Wilensky, JS**. "Disruptive Technology to Transform Healthcare." Invited Lecturer at the UC San Diego Rady School of Management, US-Israel Center on Innovation & Economic Sustainability, February 2016.

**Wilensky JS**. "Adiposity and Inflammation." Presented at the 17<sup>th</sup> Clinical Applications for Age Management Medicine, Las Vegas, NV, November 2014.

**Wilensky JS**, Newman MH. "Nasal Juvenile Xanthogranuloma." Presented at the 11<sup>th</sup> Annual Meeting of The Rhinoplasty Society, Orlando, FL, April 2006.

**Wilensky JS**, Rosenthal AH, Bradford CR, Rees RS. "The Use of a Bovine Collagen Construct for Reconstruction of Full-Thickness Scalp Defects in the Elderly Patient with Cutaneous Malignancy." *Annals of Plastic Surgery*. March 2005, Vol. 54: No. 3, 297-301.

**Wilensky JS**. "Chapter 20: Ear Reconstruction," in <u>Michigan Manual of Plastic</u> <u>Surgery</u>. Brown DL, Borschel GH (Eds). Lippincott, Williams & Wilkins Spiral Manual Series, 2004.

Posner SR, **Wilensky JS**, Dimick J, Henke PK. "A True Aneurysm of the Profunda Femoris Artery: A Case Report and Review of the English Language Literature." *Annals of Vascular Surgery*. November 2004, Vol. 18: No. 6, 740-6.

Buchman SR, Ignelzi MA, Radu C, **Wilensky JS**, Rosenthal AH, Tong L, Rhee ST, Goldstein SA. "Unique Rodent Model of Distraction Osteogenesis of the Mandible." *Annals of Plastic Surgery*. August 2002, Vol. 49: No. 2, 511-9.

Lauderdale JD, **Wilensky JS**, Oliver ER, Walton DS, and Glaser T. "3' Deletions Cause Aniridia by Preventing PAX6 Expression." *Proceedings of the National Academy of Sciences of the United States of America (PNAS)*. 2000; 97:13755-13759. http://www.pnas.org/cgi/content/full/240398797v1

Ignelzi MA, Buchman SR, Goldstein SA, Radu C, **Wilensky JS**, Rosenthal AH. "A Rat Model of Mandibular Distraction Osteogenesis," in <u>Distraction Osteogenesis</u> <u>and Tissue Engineering</u>. McNamara JA, Trotman CA (Eds). Craniofacial Growth Series #34, University of Michigan, 1998.

4 Cited Works	Recent Activity 🔻
3' deletions cause aniridia by preventing PAX6 gene expression	(P)
By James D. Lauderdale, Jonathan S. Wilensky, Edward R. Oliver, David S. Walton, Thomas M Glaser	133
Proceedings of the National Academy of Sciences of the United States of America 2000-12-05	citation
A True Aneurysm of the Profunda Femoris Artery: A Case Report and Review of the English Language Literature	লে।
By Steven Posner, Jonathan S. Wilensky, Justin B. Dimick, Peter K. Henke	চা
Annals of Vascular Surgery 2004-11-01	citation
<b>Unique rodent model of distraction osteogenesis of the mandible.</b>	(म)
By Steven R. Buchman, Michael A. Ignelzi, Caius G. Radu, Jonathan S. Wilensky, Andrew H. Rosenthal	50
Annals of Plastic Surgery 2002-11-01	citation
The use of a bovine collagen construct for reconstruction of full-thickness scalp defects in the elderly patient with cutaneous By Jonathan S. Wilensky, Andrew H. Rosenthal, Carol R. Bradford, Riley S. Rees Annals of Plastic Surgery 2005-03-01	a malignancy.

## **ACTIVITIES & INTERESTS**

Co-Developer and Designer of the **Head-n-Back to Sleep** (Basic Comfort<sup>™</sup>) sleep positioner in response to the significant increase in positional plagiocephaly among babies since the beginning of the "Back to Sleep" campaign

Climbed **Mount McKinley (Denali)**, turned d/t weather @ 19K' twice, June 28<sup>th</sup>, 2024

Climbed **Mount Aconcagua**, Normal Route, Summit, January 28<sup>th</sup>, 2023 – Second of Seven Summits

Climbed **Mount Kilimanjaro**, Machame Route, Summit, October 1<sup>st</sup>, 2022 – First of Seven Summits

**Grand Canyon** *Rim-to-Rim-to-Rim*; South Rim-to-North Rim-to South Rim, 47 miles: November 2010 (23 hours), November 2011 (22 hours), October 2012 (21 hours), October 2014 (21 hours), October 2017 (22 hours), October 2018 (21 hours), October 2019 (20 hours), October 2020 (20 hours), November 2021 (18 hours), October 2022 (17 hours), October 2023 (19 hours), October 2024 (16 hours) – 12 completions total

Climbed **Mt. Whitney** in 1 Day: August 2011 (sub-16 hours), July 2012 (sub-15 hours), August 2015 (sub-16 hours), August 2017 (sub-15 hours), August 2018 (sub-15 hours), September 2019 (sub-16 hours), August 2021 (sub-16 hours), August 2023 (sub-16 hours) – 8 completions total

Climbed Mt. Rainier via Kautz Glacier, "The Kautz Ice Chute," July 2015

Climbed Mt. Shasta via Hotlum-Bolam Ridge, "The North Face," July 2013

Climbed Mt. San Jacinto, Cactus-to-Clouds-to-Cactus, September 2012

Climbed Mt. Shasta via Avalanche Gulch, June 2012